Roche Looks To Defy The Odds In Parkinson’s Study
Others have tried and failed to target α-synuclein in Parkinson’s disease, but Roche hopes a Phase II study could deliver success later this year.
Others have tried and failed to target α-synuclein in Parkinson’s disease, but Roche hopes a Phase II study could deliver success later this year.